Is ivonib/Tosuvo a chemotherapy drug?

Ivosidenib/Tosovo (Ivosidenib) is not a traditional chemotherapy drug, but a targeted small molecule inhibitor. Chemotherapy drugs usually exert anti-tumor effects by non-specifically destroying rapidly dividing cells, and are therefore often accompanied by systemic side effects such as bone marrow suppression, alopecia, and gastrointestinal toxicity. The mechanism of action of ivonib is to selectively inhibit the activity of IDH1 mutant enzyme and block the abnormal accumulation of 2-hydroxyglutarate in tumor cells, thereby slowing down cell proliferation and malignant progression. This precise targeting mechanism allows the drug to exert anti-tumor effects while reducing damage to normal cells. The side effects are relatively mild, making it suitable for long-term use and maintenance treatment.

The targeting properties of ivonib embody the concepts of precision medicine and personalized treatment. Before use, the mutation status of IDH1 is confirmed through genetic testing, so that the drug can have a specific effect on mutant tumor cells, rather than killing cells broadly like chemotherapy. Its oral delivery method also facilitates patient management and improves compliance while reducing the impact on quality of life. Clinical experience shows that ivonib can achieve disease control in either single-agent maintenance or combination treatment strategies, but traditional chemotherapy often has limitations in tolerance and long-term application.

Therefore, ivosidenib should be classified as a targeted drug rather than a chemotherapy drug. This classification not only helps patients and doctors clarify medication strategies, but also facilitates understanding of side effect management, efficacy monitoring, and long-term follow-up arrangements. Compared with chemotherapy, targeted drugs have obvious advantages in accuracy and safety, making them of great value in the personalized treatment of IDH1 mutation-positive acute myeloid leukemia (AML) and providing a feasible path for future combination therapy or maintenance therapy.

Reference: https://www.tibsovo.com/